

Regulated information – August 27, 2014 - 7:45 a.m. CET

Agfa Press Office  
Septestraat 27  
B – 2640 Mortsel  
Belgium

Johan Jacobs  
Corporate Press Relations  
Manager

T +32 3 444 80 15  
F +32 3 444 44 85  
E [johan.jacobs@agfa.com](mailto:johan.jacobs@agfa.com)

## **Agfa-Gevaert publishes its second quarter 2014 results**

- **Group revenue impacted by the weakness in the emerging markets, adverse currency effects and the challenging conditions in the US healthcare market**
- **Gross profit margin improved by 3 percentage points**
- **Net profit grew to 28 million Euro**
- **Net debt decreased to 176 million Euro**

**Mortsel (Belgium), August 27, 2014 - Agfa-Gevaert today announced its second quarter 2014 results.**

“Our top line reflects the adverse currency effects and the continuously depressed economic conditions in certain parts of the world, including most emerging markets. In these tough circumstances, we continued to progress on our main goals. Continuing to work towards our target of delivering a double digit recurring EBITDA percentage, we further improved the gross profit margin. Furthermore, efficiency programs, targeted actions to limit the restructuring costs and positive raw material effects allowed us to post a strong net profit. Cash flow generation also continued to be strong, leading to a further decrease in net financial debt. These elements will remain our main focus points in the second half of the year. Meanwhile, we will also focus on controlling the top line evolution,” said Christian Reinaudo, President and CEO of the Agfa-Gevaert Group.

### **Agfa-Gevaert Group – second quarter 2014**

in million Euro	Q2 2013	Q2 2014	% change
Revenue	732	651	-11.1%
Gross profit (*)	211	207	-1.9%
% of revenue	28.8%	31.8%	
Recurring EBITDA (*)	56	63	12.5%
% of revenue	7.7%	9.7%	
Recurring EBIT (*)	36	46	27.8%
% of revenue	4.9%	7.1%	
Result from operating activities	67	44	
Result for the period	23	28	
Net cash from (used in) operating activities	51	32	

(\*) before restructuring and non-recurring items

The Agfa-Gevaert Group's revenue declined by 11.1 percent compared to the second quarter of 2013. On a currency comparable basis, the decline amounted to

8.3 percent. The weakness in most of the emerging markets and the unstable political situation in certain regions impacted the Group's top line. Agfa HealthCare's Imaging IT Solutions division suffered from the uncertain investment climate in the US healthcare sector. The business group's Direct Radiography business posted very strong sales growth. The hardcopy business and the Healthcare Information Solutions division also performed well.

The Group made good progress in improving the gross profit margin to 31.8 percent of revenue, versus 28.8 percent in the second quarter of 2013 and 29.3 percent in the first quarter of 2014. The Group's efficiency programs and positive raw material effects were the main drivers behind this evolution.

As a percentage of revenue, Selling and General Administration expenses amounted to 19.2 percent.

R&D expenses amounted to 37 million Euro, versus 36 million Euro in last year's second quarter.

Recurring EBITDA (the sum of Graphics, HealthCare, Specialty Products and the unallocated portion) and recurring EBIT improved to 9.7 percent and 7.1 percent of revenue respectively.

Due to targeted actions, restructuring and non-recurring items were limited to an expense of 2 million Euro. In the second quarter of 2013, these items resulted in an income of 31 million Euro, as the Group booked the effects of the closure of the post-retirement medical plan in the USA.

The net finance costs amounted to 13 million Euro, versus 21 million Euro in the second quarter of 2013.

Tax expenses amounted to 3 million Euro, versus 23 million Euro in the second quarter of 2013, when a one-off deferred (non cash) tax expense related to the closure of the post-retirement medical plan in the USA was booked.

Although last year's figures were positively influenced by the before mentioned targeted benefit actions, the Group succeeded in improving its net profit to 28 million Euro.

## Financial position and cash flow

- At the end of the quarter, total assets were 2,573 million Euro, compared to 2,568 million Euro at the end of 2013.
- Inventories amounted to 561 million Euro (107 days), versus 648 million Euro (108 days) in the second quarter of 2013. Trade receivables (minus deferred revenue and advanced payments from customers) amounted to 399 million Euro (55 days), versus 452 million Euro (56 days) in the second quarter of 2013, and trade payables were 241 million Euro (46 days), versus 259 million Euro (43 days).
- Net financial debt amounted to 176 million Euro, versus 299 million Euro at the end of last year's second quarter, and 217 million Euro at the end of 2013.
- Net cash from operating activities amounted to 32 million Euro.

## Agfa Graphics – second quarter 2014

in million Euro	Q2 2013	Q2 2014	% change
Revenue	380	339	-10.8%
Recurring EBITDA (*)	21.9	28.9	32.0%
% of revenue	5.8%	8.5%	
Recurring EBIT (*)	12.7	21.5	69.3%
% of revenue	3.3%	6.3%	

(\*) before restructuring and non-recurring items

Agfa Graphics' revenue decreased by 10.8 percent to 339 million Euro. Excluding currency related effects, the decline amounted to 8.7 percent. The business group's top line was impacted by the weakness in most of the emerging markets. In the prepress segment, the decline of the analog business continued, while the digital computer-to-plate (CtP) business continued to suffer from competitive pressure. In spite of the weak investment climate, the inkjet segment booked a profitable volume increase, driven by the success of recently released wide-format printing solutions. Also in inkjet, the revenue contribution of inks for industrial applications is starting to grow, as they are being used by an increasing number of system integrators, OEM customers and other manufacturing specialists.

Agfa Graphics' gross profit margin improved from 25.5 percent in the second quarter of 2013 to 29.5 percent. In addition to the positive raw material effects, the business group was able to improve its profitability through targeted efficiency programs and cost saving measures. As a result, recurring EBITDA reached 28.9 million Euro (8.5 percent of revenue). Recurring EBIT improved by almost 70 percent to 21.5 million Euro (6.3 percent of revenue).

In the field of mobile publishing, Agfa Graphics presented further developments of its Eversify mobile publishing software at the World Newspaper Conference in Turin (Italy). Eversify automates the workflow for publishing newspaper content on a wide variety of mobile devices, such as tablets and smartphones. One of the new features allows publishers to promote multiple titles via a single app.

In the newspaper segment of the prepress market, important contracts were signed with – among other companies – Al Ghad (Jordan), Imprensa Oficial do Estado do Rio de Janeiro (Brazil), and Asahi Shimbun (Japan). Asahi Shimbun – one of the world's largest newspaper companies – decided to start using Agfa Graphics' chemistry-free Azura printing plates for part of its production. Still in Japan, major contracts were signed with the commercial printing companies Nishikawa and Harata Printing. Also in the commercial segment, the Sungwon Adpia company - the largest web-to-print company in Korea - signed a new agreement for Azura printing plates. In Argentina, the Multiposter company will install an extensive prepress solution from Agfa Graphics for the production of billboards. The deal also includes a four-year contract for Azura plates.

In the field of inkjet, Agfa Graphics was presented three awards by the European Digital Press Association (EDP) at the FESPA Digital trade event in Munich. The EDP Awards praise the best products of the year introduced in the European market. Agfa Graphics won the award for the Asanti workflow solution for the Sign & Display market, the Jeti Titan HS wide-format printer and the Altamira LM ink technology.

In May, Agfa Graphics introduced a redesigned version of its Anapurna M2050 hybrid wide-format inkjet printer. Fully commercially available in the third quarter of 2014, the Anapurna M2050i will achieve a productivity increase of up to 75% compared to its predecessor.

Furthermore, the Anapurna and Jeti printer ranges continued to convince customers all over the world. Introduced in the second quarter of 2013, the dedicated Asanti workflow software for the sign & display markets is often named by customers as an important competitive advantage of Agfa Graphics' wide-format engines.

Phase 3 Marketing & Communications became the first US customer for Agfa Graphics' new high-speed Jeti Titan HS printing system. Other examples of companies installing machines from the Jeti Titan range are XL Media Group (Uganda and Angola), Bestia Gráfica (Argentina), and Kseroplast-Plus (Poland). The Anapurna M2500 system also continued to find its way to new markets, including Saudi Arabia, United Arab Emirates, Nigeria, Turkey and Russia.

At the first InPrint trade show (organized in Hannover, Germany), Agfa Graphics demonstrated how inkjet technology can enable businesses to integrate print into their industrial manufacturing lines. In this field, Agfa Graphics' strengths lie in the development of UV inkjet ink formulations for specific applications and in a profound knowledge of the integration of all elements in an industrial inkjet printing process.

#### Agfa HealthCare – second quarter 2014

in million Euro	Q2 2013	Q2 2014	% change
Revenue	294	263	-10.5%
Recurring EBITDA (*)	28.7	32.3	12.5%
% of revenue	9.8%	12.3%	
Recurring EBIT (*)	18.9	23.5	24.3%
% of revenue	6.4%	8.9%	

(\*) before restructuring and non-recurring items

Agfa HealthCare's revenue decreased by 10.5 percent. On a currency comparable basis, the decrease amounted to 6.4 percent. A major adverse element was the economic weakness in most of the emerging markets. This particularly affected sales of the Imaging segment's traditional film products. In the segment's digital radiography business (consisting of Computed Radiography, Direct Radiography and the hardcopy business), the DR product range posted very strong sales growth. The hardcopy business also performed well. In the IT segment, the Healthcare Information Solutions division performed well, whereas Imaging IT Solutions continued to suffer from the challenging conditions in the US healthcare market.

Agfa HealthCare's gross profit margin improved significantly from 34.7 percent of revenue to 37.6 percent. Targeted efficiency programs (e.g. in the field of service efficiency and procurement) and favorable raw material effects more than counterbalanced the adverse currency and mix effects. Recurring EBITDA reached

32.3 million Euro (or 12.3 percent of revenue). Recurring EBIT improved strongly to 23.5 million Euro (or 8.9 percent of revenue).

For Agfa HealthCare, a major highlight in the second quarter was winning Premier Inc.'s Supplier Legacy Award for operational excellence. With the award, Premier recognizes the business group's expertise in enterprise and departmental imaging IT. Premier is a leading healthcare improvement company uniting an alliance of approximately 3,000 US hospitals and 110,000 other care providers.

Also in the field of Imaging IT Solutions, Agfa HealthCare debuted its ICIS Mobile and Web Capture technology at the Society for Imaging Informatics in Medicine (SIIM) meeting in Long Beach, California. The solution enables physicians and patients to securely upload medical images from a mobile device to an electronic health record. The technology builds on Agfa HealthCare's ICIS (Imaging Clinical Information System) platform.

In the US, Agfa HealthCare will unite its ICIS solution with Hyland's OnBase content management solution. By connecting patient medical records and medical images within the Electronic Health Record (EHR), the joint solution provides all authorized persons across the hospital enterprise with real-time access to a patient's full medical history.

In Brazil, FIDI (Imaging Diagnosis Research and Study Institute) will install the first Agfa HealthCare Global Remote Incident Prevention (GRIP) solution in Latin America. The FIDI foundation administers 57 radiology units in hospitals, laboratories and other care centers. The GRIP system will continuously monitor Agfa HealthCare's RIS/PACS and teleradiology solutions used by FIDI to prevent incidents before they occur.

In the field of Imaging, Agfa HealthCare won an important tender for Direct Imaging (DR) systems in India. The business group will supply 29 DX-D 600 units to care centers in the state of West Bengal. Also in India, Agfa HealthCare will install 4 DX-M Computed Radiography (CR) solutions at PBM Hospital in Bikaner, Rajasthan. The Ministry of Health of the Kingdom of Saudi Arabia will implement three Agfa HealthCare DR solutions in three of its hospitals: the Rafha Central Hospital in Arar, the Maternity and Children's hospital in Gassim, and the Maternity and Children's hospital in Dammam. The Canadian St. Marys Hospital Site of Huron Perth Healthcare Alliance (HPHA) will install a fully motorized DX-D 600 DR

unit. In the UK, Agfa HealthCare successfully implemented three of its DX-D 30C Retrofit solutions at North Tees and Hartlepool NHS Foundation Trust. With the solution, hospitals are able to upgrade existing CR-based imaging equipment to wireless DR.

Agfa HealthCare's imaging technology is also used by veterinary clinics around the world. In May, the business group announced that it is a technical sponsor of the Mobile Horse Vet Clinic for the annual Longines Global Champions Tour 2014, running from 24 April to 15 November. Agfa HealthCare's solutions will be used to screen the horses participating in the prestigious showjumping series.

### Agfa Specialty Products – second quarter 2014

in million Euro	Q2 2013	Q2 2014	% change
Revenue	58	49	-15.5%
Recurring EBITDA (*)	6.5	3.3	-49.2%
% of revenue	11.2%	6.7%	
Recurring EBIT (*)	5.4	2.2	-59.3%
% of revenue	9.3%	4.5%	

(\*) before restructuring and non-recurring items

Mainly due to the lower silver price, Agfa Specialty Products' revenue decreased to 49 million Euro. Agfa Specialty Products' future-oriented businesses (mainly Synaps Synthetic Paper and Orgacon Electronic Materials), as well as the Printed Circuit Board business performed well.

The business group's recurring EBITDA amounted to 3.3 million Euro (6.7 percent of revenue) and recurring EBIT to 2.2 million Euro (4.5 percent of revenue).

### Results after six months

#### Agfa-Gevaert Group – year to date

in million Euro	H1 2013	H1 2014	% change
Revenue	1,437	1,273	-11.4%
Gross profit (*)	414	389	-6.0%
% of revenue	28.8%	30.6%	
Recurring EBITDA (*)	97	97	
% of revenue	6.8%	7.6%	
Recurring EBIT (*)	57	62	8.8%
% of revenue	4.0%	4.9%	
Result from operating activities	79	59	
Result for the period	11	29	
Net cash from (used in) operating activities	15	63	

(\*) before restructuring and non-recurring items

### Agfa Graphics – year to date

in million Euro	H1 2013	H1 2014	% change
Revenue	751	666	-11.3%
Recurring EBITDA (*)	35.5	49.3	38.9%
% of revenue	4.7%	7.4%	
Recurring EBIT (*)	17.1	34.1	99.4%
% of revenue	2.3%	5.1%	

(\*) before restructuring and non-recurring items

### Agfa HealthCare – year to date

in million Euro	H1 2013	H1 2014	% change
Revenue	570	507	-11.1%
Recurring EBITDA (*)	50.1	45.0	-10.2%
% of revenue	8.8%	8.9%	
Recurring EBIT (*)	30.5	27.2	-10.8%
% of revenue	5.4%	5.4%	

(\*) before restructuring and non-recurring items

### Agfa Specialty Products – year to date

in million Euro	H1 2013	H1 2014	% change
Revenue	116	100	-13.8%
Recurring EBITDA (*)	13.0	5.1	-60.8%
% of revenue	11.2%	5.1%	
Recurring EBIT (*)	10.9	2.8	-74.3%
% of revenue	9.4%	2.8%	

(\*) before restructuring and non-recurring items

End of message

#### Management Certification of Financial Statements and Quarterly Report

This statement is made in order to comply with new European transparency regulation enforced by the Belgian Royal Decree of 14 November 2007 and in effect as of 2008.

"The Board of Directors and the Executive Committee of Agfa-Gevaert NV, represented by Mr. Julien De Wilde, Chairman of the Board of Directors, Mr. Christian Reinaudo, President and CEO, and Mr. Kris Hoornaert, CFO, jointly certify that, to the best of their knowledge, the consolidated financial statements included in the report and based on the relevant accounting standards, fairly present in all material respects the financial condition and results of Agfa-Gevaert NV, including its consolidated subsidiaries. Based on our knowledge, the report includes all information that is required to be included in such document and does not omit to state all necessary material facts."

#### Statement of risk

This statement is made in order to comply with new European transparency regulation enforced by the Belgian Royal Decree of 14 November 2007 and in effect as of 2008.

"As with any company, Agfa is continually confronted with – but not exclusively – a number of market and competition risks or more specific risks related to the cost of raw materials, product liability, environmental matters, proprietary technology or litigation."

Key risk management data is provided in the annual report available on [www.agfa.com](http://www.agfa.com).

**Contact:****Viviane Dictus**

Director Corporate Communication

Septestraat 27

2640 Mortsel - Belgium

T +32 (0) 3 444 71 24

F +32 (0) 3 444 44 85

E [viviane.dictus@agfa.com](mailto:viviane.dictus@agfa.com)

**Johan Jacobs**

Corporate Press Relations Manager

T +32 (0)3/444 80 15

F +32 (0)3/444 44 85

E [johan.jacobs@agfa.com](mailto:johan.jacobs@agfa.com)

The full press release and financial information is also available on the company's website: [www.agfa.com](http://www.agfa.com)

## Consolidated Statement of Profit or Loss (in million Euro)

Unaudited, consolidated figures following IFRS accounting policies

	Q2 2013	Q2 2014	% change	H1 2013	H1 2014	% change
<b>Revenue</b>	<b>732</b>	<b>651</b>	-11.1%	<b>1,437</b>	<b>1,273</b>	-11.4%
Cost of sales	(521)	(444)	-14.8%	(1,023)	(884)	-13.6%
<b>Gross profit</b>	<b>211</b>	<b>207</b>	-1.9%	<b>414</b>	<b>389</b>	-6.0%
Selling expenses	(92)	(83)	-9.8%	(186)	(167)	-10.2%
Research & Development expenses	(36)	(37)	2.8%	(75)	(72)	-4.0%
Administrative expenses	(46)	(42)	-8.7%	(92)	(86)	-6.5%
Other operating income	77	19	-75.3%	97	35	-63.9%
Other operating expenses	(47)	(20)	-57.4%	(79)	(40)	-49.4%
<b>Results from operating activities</b>	<b>67</b>	<b>44</b>	-34.3%	<b>79</b>	<b>59</b>	-25.3%
Interest income (expense) - net	(5)	(4)	-20.0%	(9)	(8)	-11.1%
Interest income	-	1		1	1	
Interest expense	(5)	(5)		(10)	(9)	-10.0%
Other finance income (expense) - net	(16)	(9)	-43.8%	(28)	(19)	-32.1%
Other finance income	-	3		3	4	33.3%
Other finance expense	(16)	(12)	-25.0%	(31)	(23)	-25.8%
<b>Net finance costs</b>	<b>(21)</b>	<b>(13)</b>	-38.1%	<b>(37)</b>	<b>(27)</b>	-27.0%
<b>Profit (loss) before income taxes</b>	<b>46</b>	<b>31</b>	-32.6%	<b>42</b>	<b>32</b>	-23.8%
Income tax expense	(23)	(3)	-87.0%	(31)	(3)	-90.3%
<b>Profit (loss) for the period</b>	<b>23</b>	<b>28</b>	21.7%	<b>11</b>	<b>29</b>	163.6%
<b>Profit (loss) attributable to:</b>						
Owners of the Company	21	26	23.8%	8	25	212.5%
Non-controlling interests	2	2		3	4	33.3%
Results from operating activities	67	44	-34.3%	79	59	-25.3%
Restructuring and non-recurring items	31	(2)		22	(3)	
Recurring EBIT	36	46	27.8%	57	62	8.8%
Outstanding shares per end of period	167,751,190	167,751,190		167,751,190	167,751,190	
Weighted number of shares used for calculation	167,751,190	167,751,190		167,751,190	167,751,190	
Earnings per share (€)	0.13	0.15		0.05	0.15	

**Consolidated Statements of Comprehensive Income for the half year ending June 2013 / June 2014 (in million Euro)**

Unaudited, consolidated figures following IFRS accounting policies

	<b>2013</b>	<b>2014</b>
<b>Profit / (loss) for the period</b>	<b>11</b>	<b>29</b>
<b>Other Comprehensive Income, net of tax</b>		
<b>Items that may be reclassified subsequently to profit or loss:</b>		
Exchange differences:		
Exchange differences on translation of foreign operations	(8)	7
Exchange differences on net investment hedge	(1)	(1)
Income tax on exchange differences on net investment hedge	-	-
Cash flow hedges:	<b>(17)</b>	<b>8</b>
Effective portion of changes in fair value of cash flow hedges	(21)	(2)
Changes in the fair value of cash flow hedges reclassified to profit or loss	4	9
Income taxes	-	1
Available-for-sale financial assets:		
Changes in fair value of available-for-sale financial assets	-	-
Income taxes	-	-
<b>Items that will not be reclassified subsequently to profit and loss:</b>		
Remeasurements of the net defined benefit liability	-	-
<b>Total other Comprehensive Income for the period, net of tax</b>	<b>(26)</b>	<b>14</b>
<b>Total Comprehensive Income for the period attributable to:</b>	<b>(15)</b>	<b>43</b>
Owners of the Company	(19)	39
Non-controlling interests	4	4

**Consolidated Statements of Comprehensive Income for the quarter ending June 2013 / June 2014**  
**(in million Euro)**

Unaudited, consolidated figures following IFRS accounting policies

	Q2 2013	Q2 2014
<b>Profit / (loss) for the period</b>	<b>23</b>	<b>28</b>
<b>Other Comprehensive Income, net of tax</b>		
<b>Items that may be reclassified subsequently to profit or loss:</b>		
Exchange differences:		
Exchange differences on translation of foreign operations	(17)	11
Exchange differences on net investment hedge	2	(1)
Income tax on exchange differences on net investment hedge	(1)	-
Cash flow hedges:		
Effective portion of changes in fair value of cash flow hedges	(14)	-
Changes in the fair value of cash flow hedges reclassified to profit or loss	6	5
Income taxes	(3)	1
Available-for-sale financial assets:		
Changes in fair value of available-for-sale financial assets	-	-
Income taxes	-	-
<b>Items that will not be reclassified subsequently to profit and loss:</b>		
Remeasurements of the net defined benefit liability	-	-
<b>Total other Comprehensive Income for the period, net of tax</b>	<b>(27)</b>	<b>16</b>
<b>Total Comprehensive Income for the period attributable to:</b>	<b>(4)</b>	<b>44</b>
Owners of the Company	(5)	41
Non-controlling interests	1	3

## Consolidated Statement of Financial Position (in million Euro)

Unaudited, consolidated figures following IFRS accounting policies

	31/12/2013	30/06/2014
<b>ASSETS</b>		
<b>Non-current assets</b>	<b>1,066</b>	<b>1,044</b>
Intangible assets	618	609
Property, plant and equipment	242	231
Investments	11	11
Deferred tax assets	195	193
<b>Current assets</b>	<b>1,502</b>	<b>1,529</b>
Inventories	542	561
Trade receivables	585	550
Current tax assets	95	108
Other receivables and other assets	126	120
Deferred charges	25	31
Derivative financial instruments	3	1
Cash and cash equivalents	126	158
<b>Total assets</b>	<b>2,568</b>	<b>2,573</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>	<b>368</b>	<b>411</b>
<b>Equity attributable to owners of the Company</b>	<b>325</b>	<b>364</b>
Share capital	187	187
Share premium	210	210
Retained earnings	664	689
Reserves	(91)	(83)
Translation reserve	(28)	(22)
Post-employment benefits: remeasurements of the net defined benefit liability	(617)	(617)
<b>Non-controlling interests</b>	<b>43</b>	<b>47</b>
<b>Non-current liabilities</b>	<b>1,397</b>	<b>1,366</b>
Liabilities for post-employment and long-term termination benefit plans	1,002	983
Other employee benefits	11	11
Loans and borrowings	319	312
Provisions	11	10
Deferred income	1	1
Deferred tax liabilities	53	49
<b>Current liabilities</b>	<b>803</b>	<b>796</b>
Loans and borrowings	24	22
Provisions	160	150
Trade payables	239	241
Deferred revenue and advance payments	121	151
Current tax liabilities	54	59
Other payables	95	86
Employee benefits	97	80
Deferred income	3	3
Derivative financial instruments	10	4
<b>Total Equity and Liabilities</b>	<b>2,568</b>	<b>2,573</b>

## Consolidated Statement of Cash Flows (in million Euro)

Unaudited, consolidated figures following IFRS accounting policies

	6m 2013	6m 2014	Q2 2013	Q2 2014
Profit (loss) for the period	11	29	23	28
Adjustments for:				
Depreciation, amortization and impairment losses	44	35	24	17
Changes in fair value of derivative financial instruments	-1	0	-1	0
Granted subventions	-5	-4	-3	-2
(Gains) / losses on sale of non-current assets	-1	0	0	0
Net finance costs	37	27	21	13
Income tax expense	31	3	23	3
	<b>116</b>	<b>90</b>	<b>87</b>	<b>59</b>
Change in inventories	-20	-16	25	-12
Change in trade receivables	20	38	28	27
Change in trade payables	-18	10	-5	15
Change in deferred revenue and advance payments	20	29	-6	-3
Change in other working capital	-2	-6	14	11
Change in non-current provisions	-89	-39	-66	-19
Change in current provisions	-6	-31	-22	-39
<b>Cash generated from operating activities</b>	<b>21</b>	<b>75</b>	<b>55</b>	<b>39</b>
Income taxes paid	-6	-12	-4	-7
<b>Net cash from / (used in) operating activities</b>	<b>15</b>	<b>63</b>	<b>51</b>	<b>32</b>
Interest received	1	1	0	0
Dividends received	0	0	0	0
Proceeds from sale of intangible assets	1	3	1	1
Proceeds from sale of property, plant and equipment	3	1	1	0
Acquisition of intangible assets	-1	-1	-1	0
Acquisition of property, plant and equipment	-15	-12	-8	-6
Changes in lease portfolio	5	-1	3	-3
<b>Net cash from / (used in) investing activities</b>	<b>-6</b>	<b>-9</b>	<b>-4</b>	<b>-8</b>
Interest paid	-14	-13	-10	-9
Dividends paid	0	0	0	0
Proceeds from borrowings	10	0	-35	0
Repayment of borrowings	0	-10	0	0
Other financial flows	-1	0	5	-1
<b>Net cash from / (used in) financing activities</b>	<b>-5</b>	<b>-23</b>	<b>-40</b>	<b>-10</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>4</b>	<b>31</b>	<b>7</b>	<b>14</b>
<b>Cash and cash equivalents at January 1</b>	<b>125</b>	<b>125</b>		
<b>Effect of exchange rate fluctuations</b>	<b>-4</b>	<b>1</b>		
<b>Cash and cash equivalents at end of the period</b>	<b>125</b>	<b>157</b>		

## Consolidated Statement of changes in Equity (in million Euro)

Unaudited, consolidated figures following IFRS accounting policies

in million Euro	ATTRIBUTABLE TO OWNERS OF THE COMPANY										NON-CONTROLLING INTERESTS	TOTAL EQUITY
	Share capital	Share premium	Retained earnings	Reserve for own shares	Revaluation reserve	Share-based payment reserve	Hedging reserve	Remeasurements of the net defined benefit liability	Translation reserve	Total		
<b>Balance at January 1, 2013, as previously reported</b>	187	210	623	(82)	(1)	-	(2)	(808)	6	133	36	169
<b>Comprehensive income for the period</b>												
Profit (loss) for the period	-	-	8	-	-	-	-	-	-	8	3	11
Other comprehensive income, net of tax	-	-	-	-	-	-	(17)	-	(10)	(27)	1	(26)
<b>Total comprehensive income for the period</b>	-	-	8	-	-	-	(17)	-	(10)	(19)	4	(15)
<b>Balance at June 30, 2013</b>	187	210	631	(82)	(1)	-	(19)	(808)	(4)	114	40	154
<b>Balance at January 1, 2014</b>	187	210	664	(82)	1	-	(10)	(617)	(28)	325	43	368
<b>Comprehensive income for the period</b>												
Profit (loss) for the period	-	-	25	-	-	-	-	-	-	25	4	29
Other comprehensive income, net of tax	-	-	-	-	-	-	8	-	6	14	-	14
<b>Total comprehensive income for the period</b>	-	-	25	-	-	-	8	-	6	39	4	43
<b>Balance at June 30, 2014</b>	187	210	689	(82)	1	-	(2)	(617)	(22)	364	47	411